Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
Rocket Pharmaceuticals (RCKT) filed its Q3 2025 10‑Q, reporting continued investment in late-stage gene therapies without revenue. Net loss was $50.3 million for the quarter and $180.6 million for the nine months ended September 30, 2025. Operating expenses declined year over year as R&D fell to $34.1 million from $42.3 million and G&A to $18.4 million from $27.1 million, reflecting portfolio reprioritization.
Cash, cash equivalents and investments totaled $222.8 million as of September 30, 2025, and the company expects this to fund operations into the second quarter of 2027. Stockholders’ equity was $313.7 million. Rocket implemented a strategic reorganization in July 2025, reducing its workforce by ~30% and recording $3.3 million in restructuring charges year to date.
In clinical updates, the FDA lifted the clinical hold on the RP‑A501 Phase 2 trial on August 20, 2025 after the company addressed issues outlined in the hold. A prior intellectual property dispute with Lexeo was settled with no material financial impact.
Rocket Pharmaceuticals (RCKT) furnished a press release with certain financial information for the quarter ended September 30, 2025. The company submitted the release as Exhibit 99.1 under Item 2.02 of Form 8‑K.
The information is being furnished, not filed, meaning it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically referenced.
Rocket Pharmaceuticals (RCKT) reported insider transactions. A company officer sold an aggregate 28,918 shares of common stock on 10/14/2025 across multiple trades priced between $3.96 and $3.975 per share. Following these sales, the officer beneficially owned 67,006 shares, held directly. The reporting person is identified as Vice President of Finance, Treasurer, and Principal Accounting Officer. Holdings noted include RSUs that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals (RCKT) announced FDA acceptance of its resubmitted BLA for KRESLADI (marne‑cel), an investigational lentiviral gene therapy for severe Leukocyte Adhesion Deficiency‑I (LAD‑I). The agency set a PDUFA date of March 28, 2026, establishing the formal timeline for a U.S. approval decision.
KRESLADI targets a rare, life‑threatening immune disorder that often proves fatal in childhood without allogeneic stem cell transplant. If approved, the company is eligible for a Rare Pediatric Disease Priority Review Voucher, which can carry strategic value for future regulatory filings. The company attached a press release (Exhibit 99.1) and cautioned that approval is not assured, consistent with forward‑looking statement disclosures.
Insider equity awards and option grants were recorded for Rocket Pharmaceuticals (RCKT). The reporting person, the company’s Chief Medical Officer, was issued 283,018 restricted stock units (RSUs) that convert one-for-one to common shares and an additional 62,893 RSUs, for a total beneficial ownership of 345,911 shares after the transactions. The filing also shows a grant of 383,854 non-qualified stock options exercisable at $3.18 per share with an exercisable start on 10/06/2028 and expiration on 10/06/2035.
Vesting schedules are time-based: one-third of the larger RSU and option awards vest on 10/06/2026, with the remainder vesting quarterly over two years; the smaller RSU award vests half on 10/06/2026 and fully by the second anniversary. All vesting is subject to continued employment.
Peter Fong, a director of Rocket Pharmaceuticals, Inc. (RCKT), reported equity awards on a Form 4 filed for transactions dated 09/24/2025. The filing shows two grants of restricted stock units (RSUs): 23,333 RSUs that convert one-for-one to common stock and vest in full on 09/24/2026, and 30,000 RSUs that begin vesting monthly over a three-year period following 09/23/2025. Both grants are recorded with a reported price of $0, indicating they were awards rather than open-market purchases. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing discloses current beneficial ownership totals of 23,333 and 53,333 shares following the respective transactions.
Rocket Pharmaceuticals (RCKT) director Peter Fong filed a Form 3, the initial statement of beneficial ownership. The filing states that no securities are beneficially owned. The reported event date is 09/24/2025, and the form was signed by attorney-in-fact John Militello.
This is a routine Section 16 compliance filing that establishes the insider’s baseline ownership at the time of becoming a reporting person.
Rocket Pharmaceuticals reported a board change. Director Pedro Granadillo resigned from the Board of Directors, effective September 30, 2025. The company stated that his decision did not involve any disagreement on matters related to operations, policies, or practices.
Rocket Pharmaceuticals, Inc. announced it voluntarily withdrew its U.S. Biologics License Application for mozafancogene autotemcel (RP-L102 / Fanskya) on October 3, 2025. The company stopped new internal investment in RP-L102 in July 2025 and also withdrew its MAA with the EMA in July 2025, citing a corporate prioritization to focus resources on programs with clearer regulatory and commercial paths. Rocket said the withdrawal reflects business and strategic considerations and does not reflect safety or efficacy concerns; it stated that data to date show RP-L102 has been generally well tolerated with no significant safety signals. The company will consider external partnerships and reserves the ability to re-engage regulators later if a sustainable pathway emerges.
Rocket Pharmaceuticals, Inc. (RCKT) disclosed the appointment of Dr. Fong to its board of directors in a current report. The filing states there are no arrangements or understandings between Dr. Fong and any other person regarding the appointment, no family relationships between Dr. Fong and company officers or directors, and no related person transactions as defined under Regulation S-K. The notice is brief and limited to governance disclosures; it confirms the director addition and the absence of conflicts or reportable transactions, giving investors a clear, administrative update on the board composition and compliance with related‑party disclosure rules.